A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease

Movement Disorders

Volumn 26, Issue 11, 2011, Pages 2032-2038

  Gallagher, Catherine L ^a,b   Christian, Bradley T ^b,c   Holden, James E ^b   Dejesus, Onofre T ^b   Nickles, Robert J ^b   Buyan Dent, Laura ^b   Bendlin, Barbara B ^a,b   Harding, Sandra J ^a,b   Stone, Charles K ^b   Mueller, Barb ^c   Johnson, Sterling C ^a,b  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Dopamine metabolism; Parkinson's disease radionuclide imaging; Positron emission tomography

Indexed keywords

6 FLUORO META TYROSINE; 6 FLUORODOPA F 18; BIOLOGICAL MARKER; CARBIDOPA; RADIOPHARMACEUTICAL AGENT; TOLCAPONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER WALL; BRAIN; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; DOSIMETRY; DRUG EXCRETION; DRUG UPTAKE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SIDE EFFECT; SINGLE DRUG DOSE; THREE DIMENSIONAL IMAGING; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; BRAIN; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED; TYROSINE;

EID: 80052967912     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23778     Document Type: Article

References (39)

1. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
2. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003; 18(Suppl 7): S43-S51.
3. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119: 585-591.
4. Sossi V, Doudet DJ, Holden JE. A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 2001; 21: 469-476.
5. Doudet DJ, Chan GL, Jivan S, et al. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. J Cereb Blood Flow Metab 1999; 19: 278-287.
6. DeJesus OT, Holden JE, Endres C, et al. Visualization of dopamine nerve terminals by positron tomography using [18F]fluoro-beta-fluoromethylene-m-tyrosine. Brain Res 1992; 597: 151-154.
7. Firnau G, Chirakal R, Wahl L, et al. New PET tracers for cerebral dopamine: should 6-[18F]Fluoro-l-dopa be replaced. In: Emran AM, ed. Chemists Views of Imaging Centers. New York: Plenum Press; 1995: 237-247.
8. Asselin R. Patterns of distribution of [18F]-6-Fluoro-L-m-tyrosine in PET images of patients with movement disorders. In: Brain Imaging Using PET. San Diego, CA: Academic Press; 2002.
9. Mamo D, Remington G, Nobrega J, et al. Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[F-18]-L-m-tyrosine. Synapse 2004; 52: 153-162.
10. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008; 70: 1980-1983.
11. Wilcox CE, Braskie MN, Kluth JT, Jagust WJ. Overeating behavior and striatal dopamine with 6-[F]-Fluoro-L-m-Tyrosine PET. J Obes 2010 [Epub ahead of print].
12. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
13. Fahn S, Elton RL, Members UP. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: McMillan Healthcare Information; 1987: 153-163, 293-304.
14. Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 2005; 19: 165-184.
15. Nickles R, Daube M, Ruth T. An oxygen-18 gas target for the production of [F-18] F2. Int J Appl Rad Isotopes 1984; 35: 117-123.
16. Namavari M, Satyamurthy N, Phelps ME, Barrio JR. Synthesis of 6-[18F] and 4-[18F]fluoro-L-m-tyrosines via regioselective radiofluorodestannylation. Appl Radiat Isot 1993; 44: 527-536.
17. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
18. Levy G, Louis ED, Cote L, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005; 62: 467-472.
19. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001; 16: 608-615.
20. Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD Pamphlet No. 14 revised: A dynamic urinary bladder model for radiation dose calculations. Task Group of the MIRD Committee, Society of Nuclear Medicine. J Nucl Med 1999; 40: 102S-123S.
21. Brown WD, Oakes TR, DeJesus OT, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med 1998; 39: 1884-1891.
22. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006; 21: 958-963.
23. Garnett ES, Lang AE, Chirakal R, Firnau G, Nahmias C. A rostrocaudal gradient for aromatic acid decarboxylase in the human striatum. Can J Neurol Sci 1987; 14(3 Suppl): 444-447.
24. Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A 1992; 89: 10993-10997.
25. Endres CJ, Swaminathan S, DeJesus OT, et al. Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: implications for PET dopamine studies. Life Sci 1997; 60: 2399-2406.
26. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Metabolites of 6-[18F]fluoro-L-dopa in human blood. J Nucl Med 1988; 29: 363-369.
27. DeJesus OT. Positron-labeled DOPA analogs to image dopamine terminals. Drug Dev Res 2003; 59: 249-260.
28. Dejesus OT, Murali D, Nickles RJ. Synthesis of brominated and fluorinated ortho-tyrosine analogs as potential DOPA decarboxylase tracers. J Label Comp Radiopharm 1995; 37: 147-149.
29. Sossi V, de La Fuente-Fernandez R, Holden JE, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 2002; 22: 232-239.
30. Adolfsson R, Gottfries CG, Roos BE, Winblad B. Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm 1979; 45: 81-105.
31. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
32. Braskie MN, Wilcox CE, Landau SM, et al. Relationship of striatal dopamine synthesis capacity to age and cognition. J Neurosci 2008; 28: 14320-14328.
33. Doudet DJ, Chan GLY, Jivan S, et al. Evaluation of dopaminergic presynaptic integrity: 6-[F-18]fluoro-L-dopa versus 6-[F-18]fluoro-L-m-tyrosine. J Cereb Blood Flow Metab 1999; 19: 278-287.
34. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994; 44: 1292-1297.
35. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41: 58-64.
36. Eberling JL, Pivirotto P, Bringas J, Bankiewicz KS. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys. Exp Neurol 2000; 165: 342-346.
37. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009; 73: 1662-1669.
38. Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14: 564-570.
39. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520-525.